Volume : 11, Issue : 01, January – 2024
Title:
FORMULATION AND EVALUATION OF EXTENDED-RELEASE TABLETS OF AZILSARTAN USING DIFFERENT POLYMERS
Authors :
G Manohar Yadav *, L.Jyothi Rani , B.Rajkamal, B.Rama
Abstract :
The objective of the present work was to Formulate and evaluate of extended release tablets of Azilsartan by using different polymers like HPMC K100M ,Ethyl cellulose and Xanthan gum with different ratios by using direct compression method. Azilsartan is used alone or together with other medicines to treat high blood pressure (hypertension). The tablets were formulated to reduce the frequency of dose admimistration and to improve the patient compliance. The FTIR studies indicates there is no interaction between drug and polymer for optimized formulation. The pre compression and post compression parameters are with in the IP limits. The in vitro dissolution study was done for 12hrs Among all the formulations A6 formulation was shows good drug release of 99.87%. The optimized formulation were fitted to zero order, First order, higuchi release model and korsmeyer –peppas model based on the regression coefficient.
Keywords: Azilsartan, HPMC K100M ,Ethyl cellulose and Xanthan Extended release tablets.
Cite This Article:
Please cite this article in press G Manohar Yadav et al., Formulation And Evaluation Of Extended Release Tablets Of Azilsartan Using Different Polymers, Indo Am. J. P. Sci, 2024; 11 (01).
Number of Downloads : 10
References:
1. Altaf AS, Friend DR, MASRx and COSRx. Sustained-Release Technology in Rathbone MJ, Hadgraft J, Robert MS, Modified Release Drug Delivery Technology, Marcell Dekker Inc., New York, 2003; 1: 102-117.
2. Reddy KR., Mutalik S, Reddy S. AAPS Pharm. Sci. Tech.2003; 4: 19. 121-125.
3. Mohammed AD et al. Release of propranolol hydrochloride from matrix tablets containing sodium carboxymethylcellulose and Hydroxypropyl methyl cellulose. Pharm Dev Tech.1999; 4: 313-324.
4. Salsa T, Veiga F. Drug Develop. Ind Pharm. 1997; 23: 931.
5. Jantzen GM, Robinson JR, Sustained and controlled-release drug delivery systems, inBanker GS, Rhodes CT (Eds.) Modern Pharmaceutics, 3rd Ed, Revised andExpanded, Drugs and the Pharmaceutical Sciences., Marcell Dekker, Inc. NewYork. 1995; 72: 575-609.
6. Jantzen GM, Robinson JR. Sustained and Controlled- Release Drug Delivery systems Modern Pharmaceutics, 4thed; 2003; 121: 501-502.
7. Lee BJ, Ryu SG, Cui JH, Drug Dev. Ind.Pharm.1999; 25: 493-501.
8. Gwen MJ, Joseph RR, In Banker GS and Rhodes CT, Ed. Modern Pharmaceutics, 3rdEd Marcel Dekker Inc. New York. 1996; 72: 575.
9. Vidyadhara S, Rao PR, Prasad JA. Indian J Pharm Sci. 2004; 66: 188-192.
10. Bogner RH. Bioavailability and bioequivalence of extended-release oral dosage forms. US Pharmacist. 1997; 22: 3–12.
11. Rogers JD, Kwan KC. Pharmacokinetic requirements for controlled-release dosage forms. In: John Urquhart, ed. Controlled-release Pharmaceuticals. Academy of Pharmaceutical Sciences. American Pharmaceutical Association. 1979: 95–119.
12. Madan PL. Sustained-release drug delivery systems, part II: Preformulation considerations. Pharm Manu fact. 1985; 2: 41–45.
13. Wani MS, Controlled Release System-A Review, 2008; 6 1: 56-62.
14. Banker GS, Anderson NR. The Theory and Practice of Industrial Pharmacy: Tablet,Lachman, (3rded) Varghese Publishing House, Bombay. 1990; 3: 293-303.
15. Lee VHL, Controlled Drug Delivery Fundamentals and Applications: Influence of drug properties on design, Marcel Dekker, INC, and New York. 1987; 2: 16-29.